Abstract
Relationships between c-Rel and GCB-DLBCLs remain unclear. We found that strong c-Rel DNA-binding activity was mostly found in GCBs on two independent series of 48 DLBCLs and 66 DLBCLs, the latter issued from the GHEDI series. c-Rel DNA-binding activity was associated with increased REL mRNA expression. Extending the study to the whole GHEDI and Lenz DLBCL published series of 202 and 233 cases, it was found that the c-Rel gene expression profile (GEP) overlapped partially (12%) but only with the GCB GEP and not with the GEP of ABC-DLBCLs. Cases with both overexpression of REL mRNA and c-Rel GEP were defined as those having a c-Rel signature. These cases were GCBs in 88 and 83% of the GHEDI or Lenz’s DLBCL series respectively. The c-Rel signature was also associated with various recurrent GCB-DLBCL genetic events, including REL gains, BCL2 translocation, MEF2B, EZH2, CREBBP, and TNFRSF14 mutations and with the EZB GCB genetic subtype. By CGH array, the c-Rel signature was specifically correlated with 2p15-16.1 amplification that includes XPO1, BCL11A, and USP34 and with the 22q11.22 deletion that covers IGLL5 and PRAME. The total number of gene copy number aberrations, so-called genomic imbalance complexity, was decreased in cases with the c-Rel signature. These cases exhibited a better overall survival. Functionally, overexpression of c-Rel induced its constitutive nuclear localization and protected cells against apoptosis while its repression tended to increase cell death. These results show that, clinically and biologically, c-Rel is the pivotal NF-κB subunit in the GCB-DLBCL subgroup. Functionally, c-Rel overexpression could directly promote DLBCL tumorigenesis without need for further activation signals.
Highlights
Diffuse large B-cell lymphomas (DLBCL) are the most frequent among aggressive non-Hodgkin’s lymphomas (NHLs)
We studied the REL mRNA expression and DNA-binding activity on a test series of 48 DLBCLs classified as germinal center B-cell-like (GCB) (30/48) or non-GCB (18/48) according to the Hans’s algorithm
Confirming those published by Li et al [30], our results show that REL mRNA levels were higher in GCB than in ABCDLBCLs
Summary
Diffuse large B-cell lymphomas (DLBCL) are the most frequent among aggressive non-Hodgkin’s lymphomas (NHLs). Gene-expression profiling (GEP) studies led to the proposal of two cell-of-origin (COO) molecular subtypes known as germinal center B-cell-like (GCB) DLBCLs, and activated B-cell like (ABC) DLBCLs, with a subset of cases showing an intermediate, unclassifiable phenotype [1]. When compared to GCB-DLBCLs, several studies have shown that ABC-DLBCLs are the more aggressive subtype with the worst patient outcome [2, 3]. ABC-DLBCLs exhibit constitutive activation of the NF-kB pathway that drives tumor proliferation and survival and confers chemotherapy resistance [4]. Constitutive activation of NF-kB in ABC-DLBCLs is due to a variety of mutations in NF-kB regulator coding genes, such as MYD88, TNFAIP3 (A20), CD79A/B, CARD11, TRAF2, TRAF5, MAP3K7 (TAK1), or TNFRSF11A (RANK) [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
